TREATMENT UTILIZATION OF COMMERCIALLY INSURED PATIENTS UNDER 65 YEARS OF AGE DIAGNOSED WITH LATERAL EPICONDYLITIS
Author(s)
Corso K1, Wright J2, Hester D3, Nandwani P4, Parrish WR2
1Johnson & Johnson, Raynham, MA, USA, 2Johnson & Johnson, Medical Affairs, Raynham, MA, USA, 3Johnson & Johnson, Mitek Sports Medicine, Raynham, MA, USA, 4Mu Sigma, Bangalore, India
Presentation Documents
OBJECTIVES : For the treatment of lateral epicondylitis (LE), patients initially undergo non-surgical methods; traditional treatments include physical therapy, pain medications, and bracing. Recently, several non-surgical emerging therapies for LE have been introduced. To understand adoption of these therapies, this study evaluates treatment rates over time for patients diagnosed with LE. METHODS : Patients with ICD diagnosis codes, version 9/10, for LE in 2010 to 2015 were followed for one and two years after first diagnosis using IBM Marketscan Commercial Claims and Encounters database. Patients were required to be between 18 and 64 years of age, and have health plan continuous enrollment. Patient characteristics and presence of treatments from first diagnosis to two years after was collected. Treatment utilization was summarized as counts and percent treated for the overall population and by year of diagnosis. RESULTS : A total of 388,219 patients were evaluated. Patients were 51.3% female and between 45 to 54 years (44.5%). The top therapies were physical therapy 16.1%, corticosteroid injection 13.5%, bracing 5.3% and surgery (2.5%). Therapies <2% were acupuncture, platelet rich plasma, botulinum toxin, laser treatment, and prolotherapy. Treatment rates categorized by diagnosis year didn’t greatly differ from the overall rates, and two-year treatment rates increased slightly for some therapies - range for the difference was between 0.01% and 0.97%. CONCLUSIONS : Many patients with LE receive physical therapy, corticosteroid injection, and bracing, while the rate of newer non-surgical therapies is <2%. The frequency of treatments did not change over time, suggesting traditional options continue to be the mainstay of LE management. However, a limitation of this study is that many of the emerging therapies evaluated here currently lack universal payer coverage, and may be underrepresented in the database. The data also suggests that insufficient coverage of newer therapies may be associated with the apparent poor adoption rates in mainstream clinical practice.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PMS38
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Treatment Patterns and Guidelines
Disease
Musculoskeletal Disorders